Sofosbuvir in Treatment of COVID 19

Tanta University

Status and phase: Unknown; Phase 3; Phase 2

Conditions: COVID

Treatments: Drug: sofosbuvir; Drug: Sofosbuvir ledipsavir; Drug: Daclatasvir

Study type: Interventional

Funder types: Other

Identifiers

NCT04460443

sofosbuvir

Details and patient eligibility

About

Sofosbuvir containing treatment in treatment of COVID 19 Egyptian patients

Full description

Sofosbuvir containing treatment of COVID 19 Egyptian patients: a randomized-controlled trial

Enrollment: 60 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Covid positive patients.

Exclusion criteria

• Contraindication to sofosbuvir or ribavirin.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

60 participants in 3 patient groups

Sofosbuvir and ledipsavir

Experimental group

Description:

Sofosbuvir and ledipsavir plus standard of care treatment.

Treatment:

Drug: Sofosbuvir ledipsavir

Sofosbuvir and Daklatasuvir

Experimental group

Description:

Sofosbuvir and Daklatasuvir plus standard of card treatment..

Treatment:

Drug: Daclatasvir

Drug: sofosbuvir

Standard treatment

No Intervention group

Description:

Standard treatment alone